Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 571-579

  Moe, Gordon W ^a   Albernaz, Ana ^a   Naik, George O ^a   Kirchengast, Michael ^b   Stewart, Duncan J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Knoll AG   (Germany)

Author keywords

Endothelin; Heart failure; Hemodynamics; Natriuretic peptide; Remodeling

Indexed keywords

DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOG; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIAC PACING, ARTIFICIAL; DOGS; ECHOCARDIOGRAPHY; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; MALE; NOREPINEPHRINE; PHENYLPROPIONATES; PYRIMIDINES; RANDOM ALLOCATION; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; VASCULAR RESISTANCE; VENTRICULAR REMODELING;

EID: 0032168659     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00169-2     Document Type: Article

References (46)

1. Yanigasawa M., Kurihara H., Kimura S.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Eur J Physiol. 413:1988;108-110.
3. Komuro I., Kurihara H., Sugiyama T.et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 238:1988;249-252.
4. Inoue A., Yanagisawa M.M., Kimura S.et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 86:1989;2863-2867.
5. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-772.
6. Sakurai T., Yanagiswa M., Takuwa Y.et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348:1990;732.
7. A receptor. Life Sci. 50:1992;247.
8. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 89:1994;1203-1208.
9. Williams D.L., Jones K.L., Pettibone D.J., Lis E.V., Clineschmidt B.C. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptors subtypes. Biochem Biophys Res Commun. 175:1991;556.
10. B selective endothelin agonist in conscious rats. Hypertension. 20:1992;425.
11. Clozel M., Gray G.A., Breu V., Loffler B.M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 186:1992;867-873.
12. Marguiles K.B., Hildebrand F.L. Jr., Lerman A., Perella M.A., Burnett J.C. Jr. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
13. Cavero P.G., Miller W.L., Heublein D.M., Marguiles K.B., Burnett J.C. Jr. Endothelin in experimental heart failure in the anesthetized dog. Am J Physiol. 259:1990;F312-F317.
14. Underwood R.D., Aarhus L.L., Heublein D.M., Burnett J.C. Jr. Endothelin in thoracic inferior vena caval constriction model of heart failure. Am J Physiol. 263:1992;H951-H955.
15. Stewart D.J., Cernacek P., Costello K.B., Rouleau J.L. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 85:1992;510-517.
16. Wei C.M., Lerman A., Rodeheffer R.J.et al. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
17. Sakai S., Miyauchi T., Sakurai T.et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation. 93:1996;1214-1222.
18. Teerlink J.R., Loeffler B.-M., Hess P.et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 90:1994;2510-2518.
19. Sakai S., Miyauchi T., Sakurai T.et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J Am Coll Cardiol. 28:1996;1580-1588.
20. Sakai S., Miyauchi T., Kobayashi M.et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
21. Spinale F.G., Walker J., Mukherjee R.et al. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation. 95:1997;1918-1929.
22. Lenfant C. Report of the task force on research in heart failure. Circulation. 90:1994;1118-1123.
23. Armstrong P.W., Stopps T.P., Ford S.E., De Bold A.J. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 74:1986;1075-1084.
24. Moe G.W., Stopps T.P., Howard R.J., Armstrong P.W. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. J Lab Clin Med. 112:1988;426-432.
25. Howard R.J., Moe G.W., Stopps T.P., Armstrong P.W. Recovery from heart failure: structural and functional analysis of a canine model. Can J Physiol Pharmacol. 66:1988;1505-1512.
26. Riechers H., Albrecht H.P., Amberg W.et al. Discovery and optimization of a novel class of orally active nonpeptide endothelin-A receptor antagonists. J Med Chem. 39:1996;2123-2128.
27. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett. 6:1996;90-92.
28. Kucher K., Nortershauser P., Dubbers K., Kern R. First formation on the tolerability, pharmacokinetics, and pharmacodynamics of the endothelin receptor antagonist LU 135252 in healthy human subjects (Abstract). Hospitalis. 68:1998;23S.
29. Moe G.W., Angus C., Howard R.J., Parker T.G., Armstrong P.W. Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. Cardiovasc Res. 26:1992;362-366.
30. Howard R.J., Moe G.W., Armstrong P.W. Sequential echocardiographic-doppler assessment of left ventricular remodeling and mitral regurgitation during evolving experimental heart failure. Cardiovasc Res. 25:1991;468-474.
31. Moe G.W., Montgomery C., Howard R.J., Grima E.A., Armstrong P.W. Left ventricular myocardial blood flow, metabolism and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med. 121:1993;294-301.
32. Forster C., Larosa G., Armstrong P.W. Impact of enalapril therapy on in vitro coronary artery responsiveness in pacing-induced heart failure. Can J Physiol Pharmacol. 70:1992;1417-1422.
33. Moe G.W., Grima E.A., Howard R.J., Armstrong P.W. Biatrial hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure. J Cardiac Failure. 2:1996;127-132.
34. Wyatt H.L., Heng M.K., Meerbaum S.et al. Cross-sectional echocardiography. I. Analysis of mathematical model for quantifying mass of the left ventricle in dogs. Circulation. 60:1979;1104-1113.
35. Schiller N.B., Skioldebrand C.G., Schiller E.J.et al. Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation. 68:1983;210-216.
36. Ren J.F., Kotler M.N., DePace N.L.et al. Two-dimensional echocardiographic determination of left atrial emptying volume: a noninvasive index in quantifying the degree of nonrheumatic mitral regurgitation. J Am Coll Cardiol. 2:1983;729-736.
37. Moe G.W., Grima E.A., Angus C.et al. Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs. Role of changes in heart rate, atrial dimension, and cardiac tissue concentration. Circulation. 83:1991;1780-1787.
38. Shimoyama H., Sabbah H.N., Borzak S.et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation. 94:1996;779-784.
39. Kiowski W., Sutsch G., Hunziker P.et al. Evidence of endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
40. Cesari M., Pavan E., Sacchetto A., Rossi G.P. Endothelin-1: a scientist's curiosity, or a real player in ischemic heart disease? Am Heart J. 132:1996;1236-1243.
41. Moe G.W., Stopps T.P., Angus C.et al. Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. J Am Coll Cardiol. 13:1989;173-179.
42. Donckier J., Hanet C., Galanti L.et al. Low-dose endothelin-1 potentiates volume-induced secretion of atrial natriuretic factor. Am J Physiol. 263:1992;H939-H944.
43. Thibault G., Garcia D.R., Lariviere R., Schiffrin E.L. Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors. Circ Res. 74:1994;460-470.
44. Panayiotou H., Haitas B., Hollister A.S. Atrial wall tension changes and the release of atrial natriuretic factor on relief of cardiac tamponade. Am Heart J. 129:1985;960-967.
45. Grima E.A., Moe G.W., Howard R.J., Armstrong P.W. Recovery of attenuated baroreflex in conscious dogs after reversal of pacing induced heart failure. Cardiovasc Res. 28:1994;384-390.
46. Rouleau J.L. The neurohumoral hypothesis and the treatment of heart failure. Can J Cardiol. 12:1996;3F-8F.